Optical Coherence Tomography in Multiple Sclerosis Patients
To evaluate the ability of different spectral domain optical coherence tomography (OCT) devices, as well as different acquisition and analysis packages, to detect disease progression in patients with multiple sclerosis with and without a history of optic neuritis
|Study Design:||Observational Model: Case Control
Time Perspective: Prospective
|Official Title:||Optical Coherence Tomography in Multiple Sclerosis Patients|
- Thickness of retinal layer [ Time Frame: 1 day ] [ Designated as safety issue: No ]The primary outcome is to determine the thickness of the retinal layers (measured in microns) of optic neuritis-affected eye in MS patients, as compared to controls.
- Iris area [ Time Frame: 1 day ] [ Designated as safety issue: No ]Determine the area of the iris (measured in square microns) of optic neuritis-affected eye in MS patients, as compared to controls.
|Study Start Date:||August 2012|
|Study Completion Date:||June 2013|
|Primary Completion Date:||June 2013 (Final data collection date for primary outcome measure)|
Multiple sclerosis with optic neuritis
Multiple sclerosis without optic neuritis
Optical coherence tomography imaging of the retina has been shown to be an effective non invasive method to study retinal changes associated with multiple sclerosis induced optic neuritis. The retina is a unique structure in that it is an unmyelinated part of the central nervous system (CNS). However, it is uncertain which layer of the retina provides the best correlation with MS disease. The investigators propose a prospective, case-control study to compare OCT measurements from different parts of the retina of MS patients with optic neuritis, those without optic neuritis, and healthy controls. The investigators will then correlate the OCT measurements to clinical measures of disease. This will allow future studies to use OCT technology as a primary outcome in studying MS axonal and cell body injury of the CNS, as well as evaluating strategies in treating MS.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01774123
|United States, Ohio|
|Cole Eye Institute|
|Cleveland, Ohio, United States, 44195|
|Principal Investigator:||Peter K. Kaiser, MD||Cleveland Clinic Cole Eye Institute|
|Principal Investigator:||Robert Bermel, MD||Cleveland Clinic Mellen Center|